Jagsonpal Pharmaceuticals share price
NSE: JAGSNPHARMBSE: 507789Pharmaceuticals & BiotechnologySmall Cap
Jagsonpal Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1987 on BSE, Mar 2000 on NSE
Last close ₹230.96up ₹7.85 (3.52%)BSE ₹229.50
Share price at the NSE close on 28 Oct 2026. Previous close ₹223.11.
28 Oct: open ₹225.10, high ₹239.00, low ₹222.00
52-week range of traded prices to 28 Oct 2026
₹155.00Low, 22 Jan 2026₹264.50High, 30 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,526 Cr1,360th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 33.54
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 6.34
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.73%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,16,53441.3% delivered
Results
Standalone; ₹ crore.Jagsonpal Pharmaceuticals quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +6.4%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −26.6%
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹81 Crdown 1.04%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹13 Crdown 4.54%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 15.5%
Revenue by quarter
Peak revenue ₹82 Cr, quarter to Jun 2026; lowest ₹59 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 74.0 | 58.6 | 75.6 | 74.5 | 72.9 | 64.2 | 82.2 | 81.4 |
| Net profit | 32.0 | 6.6 | 10.8 | 12.6 | 11.0 | 8.8 | 13.2 | 12.6 |
| Net margin | 43.2% | 11.2% | 14.3% | 16.9% | 15.0% | 13.6% | 16.0% | 15.5% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹287 Crup 6.89%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹43 Crdown 22.18%
- Net margin
- 15.0%
Revenue by year
Peak revenue ₹287 Cr, year to Mar 2026; lowest ₹127 Cr, year to Mar 2018
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 144 | 127 | 167 | 159 | 188 | 226 | 237 | 209 | 269 | 287 |
| Net profit | 12 | −12 | 7 | 8 | 17 | 20 | 27 | 22 | 55 | 43 |
| Net margin | 8.2% | −9.1% | 4.3% | 5.0% | 9.1% | 8.7% | 11.3% | 10.8% | 20.6% | 15.0% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.Jagsonpal Pharmaceuticals PE ratio and valuation
Price to earnings
At or below today's level on 56% of 2,075 trading days over the last 10 years.
LowestHighest
Its median32.12Industry median27.98
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 75% of 1,966 trading days since Nov 2018.
LowestHighest
Its median5.05Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 94% of 2,458 trading days over the last 10 years.
LowestHighest
Its median0.75%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −13.1% | −22.5% | +9.4% | 2.2% |
| 3 years | +18.4% | +16.2% | +0.4% | 1.7% |
| 5 years | +43.7% | +19.7% | +18.7% | 1.6% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 and 3 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2023 and Mar 2025.
Mutual fund holdings
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 2 of the 2 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.
- CutCut. Funds that held fewer shares than at the end of the month before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 478 | 0.03% | ₹0.01 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 225 | 0.03% | ₹53,000 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Jagsonpal Pharmaceuticals insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade · 11 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Jagsonpal Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Jagsonpal Pharmaceuticals in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Hester BiosciencesHESTERBIO | 1,909 | 14.02 | 5.30 | +4.1% | +262.2% | 40.4% | 11.7% | 0.49% |
 Windlas BiotechWINDLAS | 1,834 | 27.61 | 3.16 | +18.5% | +2.4% | 12.2% | 12.2% | 0.71% |
 Venus RemediesVENUSREM | 1,778 | 14.61 | 2.52 | +19.3% | +73.0% | 18.7% | 21.0% | 0.75% |
 NGL Fine-ChemNGLFINE | 1,613 | 28.20 | 4.90 | +40.5% | – | 18.7% | 14.5% | 0.07% |
 Amrutanjan Health CareAMRUTANJAN | 1,425 | 26.41 | 3.85 | +10.7% | −1.0% | 15.5% | 18.0% | 0.99% |
 Bharat ParenteralsBPLPHARMA | 1,318 | – | 4.09 | −11.2% | – | – | −5.2% | 0.05% |
 Fermenta BiotechFERMENTA | 1,303 | – | 3.21 | −3.2% | – | – | 13.5% | 0.85% |
 Anlon HealthcareAHCL | 1,301 | 44.76 | 5.65 | – | – | 13.9% | 18.0% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Jagsonpal Pharmaceuticals dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹4.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 4 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹4.00 |
| 12 Sep 2025 | Final | ₹2.50 |
| 6 Sep 2024 | Final | ₹5.00 |
| 21 Aug 2023 | Final | ₹5.00 |
| 29 Oct 2021 | Interim | ₹4.00 |
| 22 Sep 2021 | Final | ₹1.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Jagsonpal Pharmaceuticals announcements
Oct 2026
28 Oct · Results
21 Oct · Board meeting
Sep 2026
23 Sep · General Updates
Jagsonpal Pharmaceuticals share price by year
Each calendar year to 2025.Jagsonpal Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 192.61 | −21.2% | 292.75 | 192.61 |
| 2024 | 244.34 | +57.1% | 304.48 | 110.26 |
| 2023 | 155.56 | +4.3% | 191.42 | 115.92 |
| 2022 | 149.10 | +108.4% | 159.22 | 64.04 |
| 2021 | 71.56 | +150.0% | 77.88 | 29.42 |
| 2020 | 28.62 | +178.4% | 29.54 | 6.68 |
| 2019 | 10.28 | −17.9% | 12.64 | 8.42 |
| 2018 | 12.52 | −17.8% | 17.90 | 9.16 |
| 2017 | 15.24 | +11.9% | 19.56 | 12.08 |
| 2016 | 13.62 | −30.3% | 24.06 | 10.90 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 221.21 | 228.80 | 219.22 | 223.11 | 223.55 | 46,739 | 44.2% |
| 26 Oct 2026 | 211.64 | 225.58 | 211.63 | 223.06 | 218.97 | 85,481 | 36.8% |
| 23 Oct 2026 | 210.86 | 215.58 | 203.41 | 211.76 | 210.10 | 70,162 | 45.8% |
| 22 Oct 2026 | 215.68 | 217.78 | 208.62 | 210.86 | 212.97 | 65,521 | 53.0% |
| 21 Oct 2026 | 219.30 | 222.22 | 210.01 | 217.91 | 215.29 | 79,054 | 53.7% |
| 19 Oct 2026 | 218.00 | 220.89 | 214.00 | 217.67 | 217.11 | 1,44,570 | 73.7% |
| 16 Oct 2026 | 220.70 | 222.24 | 217.20 | 218.37 | 218.23 | 47,796 | 62.5% |
| 15 Oct 2026 | 224.60 | 224.60 | 218.20 | 219.10 | 220.26 | 44,525 | 61.2% |
| 14 Oct 2026 | 221.95 | 226.98 | 220.00 | 223.85 | 223.76 | 51,897 | 50.4% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 8 Jan 2025 | Split | 0.4000 | Every 2 shares became 5. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- JAGSNPHARM
- BSE code
- 507789
- ISIN
- INE048B01035
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.jagsonpal.com
- CIN
- L74899DL1978PLC009181
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1978
- Registered office
- Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi 110020, Delhi
- Share registrar
- MCS Share Transfer Agent Ltd
- Keeps the register of shareholders and handles transfers and dividend payments